WO2002094288A1 - Compositions veterinaires comprenant des derives d'oxime avermectine et du praziquantel - Google Patents
Compositions veterinaires comprenant des derives d'oxime avermectine et du praziquantel Download PDFInfo
- Publication number
- WO2002094288A1 WO2002094288A1 PCT/IB2002/001025 IB0201025W WO02094288A1 WO 2002094288 A1 WO2002094288 A1 WO 2002094288A1 IB 0201025 W IB0201025 W IB 0201025W WO 02094288 A1 WO02094288 A1 WO 02094288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- praziquantel
- selamectin
- monosaccharide
- formulation
- treatment
- Prior art date
Links
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 229960002957 praziquantel Drugs 0.000 title claims abstract description 93
- 239000000203 mixture Substances 0.000 title claims description 60
- 229960002245 selamectin Drugs 0.000 claims abstract description 69
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 claims abstract description 67
- 239000005660 Abamectin Substances 0.000 claims abstract description 30
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 claims abstract description 26
- -1 selamectin Chemical compound 0.000 claims abstract description 6
- 238000009472 formulation Methods 0.000 claims description 46
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 34
- QCAHUFWKIQLBNB-UHFFFAOYSA-N 3-(3-methoxypropoxy)propan-1-ol Chemical compound COCCCOCCCO QCAHUFWKIQLBNB-UHFFFAOYSA-N 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 26
- 241000242722 Cestoda Species 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- 206010061217 Infestation Diseases 0.000 claims description 14
- 230000003071 parasitic effect Effects 0.000 claims description 11
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- 241000002163 Mesapamea fractilinea Species 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000004544 spot-on Substances 0.000 claims description 2
- 238000002648 combination therapy Methods 0.000 abstract description 4
- 230000002141 anti-parasite Effects 0.000 abstract description 3
- 239000003096 antiparasitic agent Substances 0.000 abstract description 3
- 241000282326 Felis catus Species 0.000 description 40
- 239000000243 solution Substances 0.000 description 18
- 241000282472 Canis lupus familiaris Species 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 8
- 208000026368 Cestode infections Diseases 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 241000935794 Dipylidium Species 0.000 description 4
- 241000244156 Hydatigera taeniaeformis Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- 241000935792 Dipylidium caninum Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 231100000313 clinical toxicology Toxicity 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 241000244206 Nematoda Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000244155 Taenia Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 244000078703 ectoparasite Species 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- PBYJDHRFPFHVKZ-UHFFFAOYSA-N n,n-dibutyl-4-hexoxynaphthalene-1-carboximidamide;hydrochloride Chemical compound Cl.C1=CC=C2C(OCCCCCC)=CC=C(C(=N)N(CCCC)CCCC)C2=C1 PBYJDHRFPFHVKZ-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940075304 praziquantel injectable solution Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940102101 selamectin topical solution Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- WGYZMNBUZFHYRX-UHFFFAOYSA-N 1-(1-methoxypropan-2-yloxy)propan-2-ol Chemical compound COCC(C)OCC(C)O WGYZMNBUZFHYRX-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 241001626718 Anoplocephala Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001660203 Gasterophilus Species 0.000 description 1
- 241000244187 Parascaris Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241001126263 Strongylidae Species 0.000 description 1
- 241001672170 Taenia pisiformis Species 0.000 description 1
- 229950008167 abamectin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000002598 avermectinlike Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 1
- 229960003997 doramectin Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000408 embryogenic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 1
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 description 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 1
- 229960004816 moxidectin Drugs 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention described herein relates to the provision of a combination therapy in the field of treatment (including prophylaxis) of parasitic infestations and consequences thereof, particularly in veterinary medicine.
- the invention relates to antiparasitic therapy using a combination of avermectin- like compounds, specifically 13-monosaccharide-5-oxime compounds, and praziquantel.
- EP 0 717 993 describes a synergistic combination of avermectins/milbemycins with praziquantel, in particular for the treatment of cestode and nematode infestations in horses.
- Particular species mentioned therein include Anoplocephala perfiolata, Strongylidae, Gasterophilus spp., and Parascari aquorum.
- Particular avermectins mentioned therein include ivermectin, abamectin, moxidectin and doramectin.
- Formulations of selamectin in di(C 2 -4 glycol) mono(C ⁇ -4 alkyl) ethers including dipropylene glycol monomethyl ether (DPGMME), and alcohols such as ethanol and isopropy alcohol (IPA) are disclosed in International Patent Application, publication no. WO00/30449, herein incorporated by reference.
- DPGMME dipropylene glycol monomethyl ether
- IPA isopropy alcohol
- Selamectin is the active ingredient of the product marketed under the trade names RevolutionTM, StrongholdTM, etc. by Pfizer Inc. and associated companies, particularly for the treatment (including prophylaxis) of endo- and ecto-parasite infestations in companion animals such as cats and dogs.
- Praziquantel is 2-(cyclohexylcarbonyl)-1 ,2,3,6,7-11b-hexahydro-4H- pyrazino[2,1-a]isoquinolin-4-one, also known as an active ingredient in EMBAY 8440TM, BiltricideTM, CesolTM, and DroncitTM. It is mentioned in the Merck Index, 11th edition, para.7714, and references therein, herein incorporated by reference.
- Desirable attributes in particular for a topical application for administration to companion animals such as cats and dogs, and especially in relation to a treatment for the control of flea, heartworm and tapeworm infestation, include: efficacy; persistence of efficacy; low volume; cosmetically acceptable; convenient; need for small number of applications for broad spectrum parasite control; compliant treatment; safe; suitable pharmacokinetic profile; suitable transdermal flux profile; rapid rate of onset; low dose of active ingredient(s); cutaneous tolerability; and stability on storage.
- Praziquantel has a widespread use in animals orally at higher doses than those which we have tested.
- Dr. J.A. Shmidl in Shawnee, Kansas treated two cats orally with doses of 25 and 50 mg/kg. There were no signs of clinical toxicity or evidence of gross lesions in the gastrointestinal tract.
- Dr. S.M. Kruckenberg reports on the oral treatment of seven cats (6 females and 1 male) with a 5 mg/kg dose during all critical periods of reproduction. Two groups of seven cats (6 females and 1 male) each were also treated subcutaneously and intramuscularly with a praziquantel injectable solution with a 5 mg/kg dose during all critical periods of reproduction. Dr. Kruckenberg further evaluated the oral use of praziquantel in one male and three female cats in a controlled study. Two groups of 4 cats (1 male and 3 females) each were also treated subcutaneously and intramuscularly with the praziquantel injectable solution. All treated cats received 3X the label rate. Four females and 1 male served as untreated controls.
- the treated males received 7 treatments at 2-week intervals throughout the breeding season. Each treated female received a treatment prior to breeding, during the embryogenic period of pregnancy, during late pregnancy and again during lactation.
- the study confirmed the lack of effects on fertility, conception, fetal development or pregnancy when praziquantel was administered at 3X dosage levels.
- Dr. Shmidl further treated two kittens (4 1/2 to 7 1/2 weeks old) twice at a 14- day interval.
- the dosage rate was 5X the label dose. Slight depression was observed in one kitten. No significant clinical toxicity signs or clinical pathology and histopathology changes were attributed to this dosage rate.
- the safety index for the use of praziquantel tablets in cats has been derived from controlled studies using the final tablet formulation (vomiting was the only effect with dual treatments of 100 mg/kg at a 14-day interval). Vomiting at high dosage rates is the typical reaction which prevents significant clinical toxicity signs from occurring.
- the safety factor is at least 5X the label rate when the product is administered at 14 day intervals to kittens 5 1/2 weeks of age and older.
- CUTTER Tape-Tabs (praziquantel) Tapeworm Tablets will remove the common tapeworms, Dipylidium caninum and Taenia taeniaeformis , from cats and kittens.
- CUTTER Tape-Tabs (praziquantel) Tapeworm Tablets for Cats and Kittens are sized for easy administration to either adult cats or kittens.
- the tablets may be given directly in the mouth or crumbled and mixed with the food.
- praziquantel tablets were 100% effective in the treatment of tapeworm infections of dogs and cats due to Taenia pisiformis , Taenia taeniaeformis and Dipylidium caninum. Additionally praziquantel effectively (100%) eliminated experimental T. taeniaeformis infections as young as seven (7) days from cats. Summary of Preclinical Effectiveness Data for Praziquantel Tablets in Cats
- praziquantel has a solubility above 60 mg/g (6% w/w) even in the presence of selamectin at up to 120 mg/g (12% w/w). Above 50% IPA however, this solubility may be increased to over 90 mg/g (9% w/w) in the supersaturated state.
- a series of IPA / DPGMME mixtures were prepared in duplicate as outlined in Table 1. To these were added a fixed amount of selamectin to provide a constant concentration of 120 mg per ml i.e. the maximum selamectin concentration found in StrongholdTM.
- Praziquantel was analysed using an gradient HPLC method modified from that developed for selamectin. This method was validated with respect to praziquantel linearity over the range 10 to 200 mg per ml of praziquantel (in the solubility test solutions) and in the presence of 120 mg per ml of selamectin. This same method was also used to check on the selamectin content in these same solutions.
- compositions containing selamectin and praziquantel are shown below, wherein the composition within the formulation is expressed % weight by volume:
- An aspect of the invention is the provision of a combination therapy using a formulation comprising a 13-monosaccharide 5-oxime avermectin such as selamectin at around 6-12% w/v, and praziquantel at around 3-9% w/v (preferably around 6% w/v), in a veterinarily acceptable carrier, diluent or adjuvant.
- a formulation comprising a 13-monosaccharide 5-oxime avermectin such as selamectin at around 6-12% w/v, and praziquantel at around 3-9% w/v (preferably around 6% w/v), in a veterinarily acceptable carrier, diluent or adjuvant.
- the (13-monosaccharide 5-oxime avermectin such as selamectin)- containing formulation comprises a di(C 2 - 4 glycol) mono(C 1 ⁇ alkyl) ether and an optional skin-acceptable solvent.
- the (13-monosaccharide 5-oxime avermectin such as selamectin)- containing formulation is suitable for topical, preferably spot-on, application.
- Another aspect of the invention is the provision of an antiparasitic combination therapy whereby a 13-monosaccharide 5-oxime avermectin such as selamectin is provided at around 6-12mg/kg (re. host animal) and praziquantel is provided at up to 18mg/kg (re. host animal).
- a 13-monosaccharide 5-oxime avermectin such as selamectin is provided at around 6-12mg/kg (re. host animal) and praziquantel is provided at up to 18mg/kg (re. host animal).
- the selamectin is present in the formulation at about 1 % to about 16% (w/v), more preferably about 4% to about 12% w/v, and most preferably about 6% to about 12% w/v.
- Specific preferred formulations contain selamectin at about 6% w/v and about 12% w/v.
- the praziquantel is present in the formulation at about 0.5 to about 10% w/v, more preferably about 3 to about 9% w/v , most preferably about 6% w/v.
- the di(C 2-4 glycol) mono(C ⁇ - alkyl) ether is diethylene glycol monomethyl ether (DEGMME) or dipropylene glycol monomethyl ether (DPGMME), more preferably DPGMME.
- DEGMME diethylene glycol monomethyl ether
- DPGMME dipropylene glycol monomethyl ether
- the skin-acceptable solvent is present and is ethanol or isopropanol, more preferably isopropanol.
- the formulation containing the avermectin 13-monosaccharide oxime has a w/v to v/v ratio of avermectin 13-monosaccharide oxime to the glycol monomethyl ether is in the range (0.5 to 2) to 1 , more preferably (0.7 to 1.4) to 1 , yet more preferably (0.9 to 1.1 ) to 1 , most preferably about 1 :1.
- a preferred formulation according to the invention also contains antioxidant, preferably selected from propylgallate, BHA (2-t-butyl-4-methoxyphenol), and BHT (2,6-di-f-butyl-4-methylphenol), more preferably BHT.
- antioxidant preferably selected from propylgallate, BHA (2-t-butyl-4-methoxyphenol), and BHT (2,6-di-f-butyl-4-methylphenol), more preferably BHT.
- a preferred formulation according to the invention consists of:
- DEGMME or DPGMME at 1 to 16% w/v, and at a w/v or v/v ratio of active compound to DEGMME/DPGMME of about 1 :1 ;
- a more preferred formulation consists of (a) selamectin at a level of 6% to 12% w/v;
- a pharmaceutical or veterinary composition which comprises a 13- monosaccharide 5-oxime avermectin such as selamectin and praziquantel and a pharmaceutical or veterinary carrier;
- kits useful in the treatment of a parasitic infestation of flea and/or heartworm and tapeworm in a mammal which comprises a 13- monosaccharide 5-oxime avermectin, such as selamectin, and praziquantel and a pharmaceutical or veterinary carrier, and instructions for the treatment of a parasitic infestation of flea and/or heartworm and tapeworm in a mammal.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02716978A EP1381374A1 (fr) | 2001-04-04 | 2002-03-28 | Compositions veterinaires comprenant des derives d'oxime avermectine et du praziquantel |
CA002443068A CA2443068A1 (fr) | 2001-04-04 | 2002-03-28 | Compositions veterinaires comprenant des derives d'oxime avermectine et du praziquantel |
JP2002591005A JP2004526804A (ja) | 2001-04-04 | 2002-03-28 | アベルメクチンオキシム誘導体およびプラジクアンテルを含む獣医学的組成物 |
BR0208654-9A BR0208654A (pt) | 2001-04-04 | 2002-03-28 | Composições veterinárias compreendendo derivados de avermectina-oxima e praziquantel |
MXPA03009023A MXPA03009023A (es) | 2001-04-04 | 2002-03-28 | Composiciones veterinarias que comprenden derivados de oximaavermectina y praziquantel. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0108485.4 | 2001-04-04 | ||
GBGB0108485.4A GB0108485D0 (en) | 2001-04-04 | 2001-04-04 | Combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002094288A1 true WO2002094288A1 (fr) | 2002-11-28 |
Family
ID=9912257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/001025 WO2002094288A1 (fr) | 2001-04-04 | 2002-03-28 | Compositions veterinaires comprenant des derives d'oxime avermectine et du praziquantel |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1381374A1 (fr) |
JP (1) | JP2004526804A (fr) |
BR (1) | BR0208654A (fr) |
CA (1) | CA2443068A1 (fr) |
GB (1) | GB0108485D0 (fr) |
MX (1) | MXPA03009023A (fr) |
WO (1) | WO2002094288A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1610613A2 (fr) * | 2003-04-04 | 2006-01-04 | Merial Ltd. | Formulations veterinaires anthelminthiques topiques |
US7763583B2 (en) | 2003-12-13 | 2010-07-27 | Bayer Animal Health Gmbh | Endoparasiticidal compositions for topical application |
WO2010107791A2 (fr) | 2009-03-17 | 2010-09-23 | Concert Pharmaceuticals, Inc. | Composés de pyrazinoisoquinoline |
US9233100B2 (en) | 2012-02-06 | 2016-01-12 | Merial, Inc. | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof |
US9237751B2 (en) | 2009-03-27 | 2016-01-19 | Norbrook Laboratories Limited | Topical parasiticide composition |
US9770449B2 (en) | 2010-04-02 | 2017-09-26 | Merial Inc. | Parasiticidal compositions comprising multiple active agents, methods and uses thereof |
US11285101B2 (en) | 2012-04-04 | 2022-03-29 | Intervet Inc. | Soft chewable pharmaceutical products |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2936710B1 (fr) * | 2008-10-07 | 2011-01-07 | Ceva Sante Animale | Composition veterinaire antiprolactinique destinee aux ruminants |
JP5723567B2 (ja) * | 2010-08-06 | 2015-05-27 | 丸石製薬株式会社 | 含窒素複素環式化合物の定量方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994015944A1 (fr) * | 1993-01-18 | 1994-07-21 | Pfizer Limited | Nouveaux agents antiparasitaires apparentes aux milbemycines et aux avermectines |
WO1995005181A2 (fr) * | 1993-08-12 | 1995-02-23 | Biovet-Joint Stock Company | Agent anti-parasitaire destine aux animaux |
EP0717993A2 (fr) * | 1994-11-28 | 1996-06-26 | Virbac S.A. | Compositions antihelmintiques pour équidés |
WO1998006407A1 (fr) * | 1996-07-30 | 1998-02-19 | Ashmont Holdings Limited | Formulations anti-helminthes |
WO2000030449A1 (fr) * | 1998-11-19 | 2000-06-02 | Pfizer Limited | Formulations antiparasitaires |
-
2001
- 2001-04-04 GB GBGB0108485.4A patent/GB0108485D0/en not_active Ceased
-
2002
- 2002-03-28 EP EP02716978A patent/EP1381374A1/fr not_active Withdrawn
- 2002-03-28 WO PCT/IB2002/001025 patent/WO2002094288A1/fr not_active Application Discontinuation
- 2002-03-28 BR BR0208654-9A patent/BR0208654A/pt not_active IP Right Cessation
- 2002-03-28 CA CA002443068A patent/CA2443068A1/fr not_active Abandoned
- 2002-03-28 MX MXPA03009023A patent/MXPA03009023A/es unknown
- 2002-03-28 JP JP2002591005A patent/JP2004526804A/ja not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994015944A1 (fr) * | 1993-01-18 | 1994-07-21 | Pfizer Limited | Nouveaux agents antiparasitaires apparentes aux milbemycines et aux avermectines |
WO1995005181A2 (fr) * | 1993-08-12 | 1995-02-23 | Biovet-Joint Stock Company | Agent anti-parasitaire destine aux animaux |
EP0717993A2 (fr) * | 1994-11-28 | 1996-06-26 | Virbac S.A. | Compositions antihelmintiques pour équidés |
WO1998006407A1 (fr) * | 1996-07-30 | 1998-02-19 | Ashmont Holdings Limited | Formulations anti-helminthes |
WO2000030449A1 (fr) * | 1998-11-19 | 2000-06-02 | Pfizer Limited | Formulations antiparasitaires |
Non-Patent Citations (3)
Title |
---|
BENCHAOUI H A ET AL: "Efficacy and safety of selamectin against fleas on dogs and cats presented as veterinary patients in Europe.", VETERINARY PARASITOLOGY, vol. 91, no. 3-4, 2000, pages 223 - 232, XP002202199, ISSN: 0304-4017 * |
BISHOP B F ET AL: "PREFACE; Selamectin: A novel broad-spectrum endectocide for dogs and cats.", VETERINARY PARASITOLOGY, vol. 91, no. 3-4, 2000, pages 161 - 162, XP002202197, ISSN: 0304-4017 * |
BISHOP B F ET AL: "Selamectin: A novel broad-spectrum endectocide for dogs and cats.", VETERINARY PARASITOLOGY, vol. 91, no. 3-4, 2000, pages 163 - 176, XP002202198, ISSN: 0304-4017 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1610613A2 (fr) * | 2003-04-04 | 2006-01-04 | Merial Ltd. | Formulations veterinaires anthelminthiques topiques |
JP2006522154A (ja) * | 2003-04-04 | 2006-09-28 | メリアル リミテッド | 動物用駆虫局所製剤 |
EP1610613A4 (fr) * | 2003-04-04 | 2012-05-02 | Merial Ltd | Formulations veterinaires anthelminthiques topiques |
US7763583B2 (en) | 2003-12-13 | 2010-07-27 | Bayer Animal Health Gmbh | Endoparasiticidal compositions for topical application |
WO2010107791A2 (fr) | 2009-03-17 | 2010-09-23 | Concert Pharmaceuticals, Inc. | Composés de pyrazinoisoquinoline |
US9237751B2 (en) | 2009-03-27 | 2016-01-19 | Norbrook Laboratories Limited | Topical parasiticide composition |
US9770449B2 (en) | 2010-04-02 | 2017-09-26 | Merial Inc. | Parasiticidal compositions comprising multiple active agents, methods and uses thereof |
US9233100B2 (en) | 2012-02-06 | 2016-01-12 | Merial, Inc. | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof |
US9259417B2 (en) | 2012-02-06 | 2016-02-16 | Merial, Inc. | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof |
US9931320B2 (en) | 2012-02-06 | 2018-04-03 | Merial Inc. | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof |
US10596156B2 (en) | 2012-02-06 | 2020-03-24 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof |
US11285101B2 (en) | 2012-04-04 | 2022-03-29 | Intervet Inc. | Soft chewable pharmaceutical products |
US11337917B2 (en) | 2012-04-04 | 2022-05-24 | Intervet Inc. | Soft chewable pharmaceutical products |
Also Published As
Publication number | Publication date |
---|---|
EP1381374A1 (fr) | 2004-01-21 |
BR0208654A (pt) | 2004-03-09 |
CA2443068A1 (fr) | 2002-11-28 |
MXPA03009023A (es) | 2004-02-12 |
GB0108485D0 (en) | 2001-05-23 |
JP2004526804A (ja) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6797701B2 (en) | Antiparasitic formulations | |
US20070010464A1 (en) | Avermectin and praziquantel combination therapy | |
AU695582B2 (en) | Anthelmintic formulations | |
JPH0623100B2 (ja) | 改良された抗寄生虫活性を持つ非水性イベルメクチン処方剤 | |
WO2003072113A1 (fr) | Composition anti-parasitaire longue duree contenant un compose salicylanilide, une espece polymerique et au moins un autre compose anti-parasite | |
EP0697814B1 (fr) | Formulations destinees au traitement cutane par deversement, contenant une substance polymere, des glycols et des glycerides | |
EP1381374A1 (fr) | Compositions veterinaires comprenant des derives d'oxime avermectine et du praziquantel | |
US20050245468A1 (en) | Anthelmintic composition | |
EP2895168A2 (fr) | Formulations pharmaceutiques de tétrandrine et procédé associé | |
US20140221299A1 (en) | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation | |
WO2001064222A1 (fr) | Compositions veterinaires destinees au traitement de maladies parasitaires | |
AU2001235489A1 (en) | Veterinary compositions for the treatment of parasitic diseases | |
CN115671040B (zh) | 一种控制动物寄生虫感染的外用制剂 | |
CN110721152A (zh) | 一种治疗动物皮肤寄生虫、真菌感染的缓释组合物 | |
WO1998018463A1 (fr) | Formulation anthelmintique | |
Buchmann et al. | Effect of ivermectin, pyrantel and morantel on the European eel and its monogenean parasites | |
Paul et al. | Efficacy of ivermectin against Dirofilaria immitis in cats 30 and 45 days post-infection. | |
US20090017089A1 (en) | Multiple active agents such as anthelmintics sustained release delivery device | |
Ekinci et al. | ANTIPARASITIC DRUGS USED THE IN TREATMENT OF DEMODICOSIS IN DOGS: 2022 LITERATURE REVIEW | |
EP1713468B1 (fr) | Composition anthelminthique | |
NZ537760A (en) | Worming formulations comprising a macrocyclic lactone and piperonyl butoxide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002716978 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2443068 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/009023 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002591005 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002716978 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002716978 Country of ref document: EP |